Abstract:In this issue of Blood , Nguyen et al 1 use in vitro and in vivo models of hyperhemolysis in sickle cell disease (SCD) to study some of the disease's most life-threatening complications for which treatment options continue to remain largely supportive in nature. Using this approach, they demonstrate that microparticles from red blood cells (RBCs) lead to the same type of endothelial injury observed in severe complications of SCD. By leveraging these models, they also discover the novel ability of carbon monoxide (CO)-releasing molecule CORM-401 to reduce hemolysis-induced endothelial injury and organ damage, providing a possible treatment strategy for hyperhemolysis-associated SCD complications.

COping with acute sickle cell hemolysis